View Financial HealthARCpoint 배당 및 자사주 매입배당 기준 점검 0/6ARCpoint 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-63.1%자사주 매입 수익률총 주주 수익률-63.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 11ARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.공시 • Jun 10Arcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.공시 • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.공시 • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.공시 • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.공시 • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.공시 • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.공시 • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ARCP.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ARCP.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장ARCpoint 배당 수익률 vs 시장ARCP.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ARCP.F)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.2%업계 평균 (Healthcare)1.9%분석가 예측 (ARCP.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARCP.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARCP.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARCP.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ARCP.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/07 00:32종가2026/05/05 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ARCpoint Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 11ARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.
공시 • Jun 10Arcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.
공시 • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.
공시 • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.
공시 • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.
공시 • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.
공시 • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.
공시 • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.